Advertisement

Practice parameter for the diagnosis and management of primary immunodeficiency

Published:September 11, 2015DOI:https://doi.org/10.1016/j.jaci.2015.04.049
      The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI) have jointly accepted responsibility for establishing the “Practice parameter for the diagnosis and management of primary immunodeficiency.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.

      Abbreviations used:

      AAAAI (American Academy of Allergy, Asthma & Immunology), ACAAI (American College of Allergy, Asthma & Immunology), HSCT (Hematopoietic stem cell therapy), JCAAI (Joint Council of Allergy, Asthma & Immunology), PIDD (Primary immunodeficiency disease), SCID (Severe combined immunodeficiency), SS (Summary statement)
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Allergy and Clinical Immunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shearer W.T.
        • Buckley R.H.
        • Engler R.J.
        • Finn Jr., A.F.
        • Fleisher T.A.
        • Freeman T.M.
        • et al.
        Practice parameters for the diagnosis and management of immunodeficiency. The Clinical and Laboratory Immunology Committee of the American Academy of Allergy, Asthma, and Immunology (CLIC-AAAAI).
        Ann Allergy Asthma Immunol. 1996; 76: 282-294
        • Bonilla F.A.
        • Bernstein I.L.
        • Khan D.A.
        • Ballas Z.K.
        • Chinen J.
        • Frank M.M.
        • et al.
        Practice parameter for the diagnosis and management of primary immunodeficiency.
        Ann Allergy Asthma Immunol. 2005; 94: S1-S63
        • Al-Herz W.
        • Bousfiha A.
        • Casanova J.L.
        • Chatila T.
        • Conley M.E.
        • Cunningham-Rundles C.
        • et al.
        Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency.
        Front Immunol. 2014; 5: 162
        • Shekelle P.G.
        • Woolf S.H.
        • Eccles M.
        • Grimshaw J.
        Developing clinical guidelines.
        West J Med. 1999; 170: 348-351
        • Stasia M.J.
        • Li X.J.
        Genetics and immunopathology of chronic granulomatous disease.
        Semin Immunopathol. 2008; 30: 209-235
        • Yel L.
        Selective IgA deficiency.
        J Clin Immunol. 2010; 30: 10-16
        • Boyle J.M.
        • Buckley R.H.
        Population prevalence of diagnosed primary immunodeficiency diseases in the United States.
        J Clin Immunol. 2007; 27: 497-502
        • Notarangelo L.D.
        Primary immunodeficiencies.
        J Allergy Clin Immunol. 2010; 125: S182-S194
        • Kwan A.
        • Abraham R.S.
        • Currier R.
        • Brower A.
        • Andruszewski K.
        • Abbott J.K.
        • et al.
        Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.
        JAMA. 2014; 312: 729-738
        • Chinen J.
        • Paul M.E.
        • Shearer W.T.
        Approach to the Evaluation of the immunodeficient patient.
        in: Rich R.R. Fleisher T.A. Shearer W.T. Schroeder Jr., H.W. Frew A. Weyand C. Clinical immunology: principles and practice. Elsevier, London2012: 1-31
        • Rezaei N.
        • Bonilla F.A.
        • Sullivan K.E.
        • de Vries E.
        • Orange J.S.
        An introduction to primary immunodeficiency diseases.
        in: Rezaei N. Aghamohammadi A. Notarangelo L. Primary immunodeficiency diseases: definition, diagnosis, management. Springer-Verlag, Berlin2008: 1-38
        • Vale A.M.
        • Schroeder Jr., H.W.
        Clinical consequences of defects in B-cell development.
        J Allergy Clin Immunol. 2010; 125: 778-787
        • Gaschignard J.
        • Levy C.
        • Chrabieh M.
        • Boisson B.
        • Bost-Bru C.
        • Dauger S.
        • et al.
        Invasive pneumococcal disease in children can reveal a primary immunodeficiency.
        Clin Infect Dis. 2014; 59: 244-251
        • Carneiro-Sampaio M.
        • Coutinho A.
        Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies.
        Adv Immunol. 2007; 95: 51-82
        • de Miranda N.F.
        • Bjorkman A.
        • Pan-Hammarstrom Q.
        DNA repair: the link between primary immunodeficiency and cancer.
        Ann N Y Acad Sci. 2011; 1246: 50-63
        • Shah S.S.
        • Bacino C.A.
        • Sheehan A.M.
        • Shearer W.T.
        Diagnosis of primary immunodeficiency: let your eyes do the talking.
        J Allergy Clin Immunol. 2009; 124: 1363-1364.e1
        • Shearer W.T.
        • Cunningham-Rundles C.
        • Ballow M.
        • Ochs H.D.
        • Geha R.S.
        Images in immunodeficiency.
        J Allergy Clin Immunol. 2007; 120: 982-984
        • Dykewicz M.S.
        • Hamilos D.L.
        Rhinitis and sinusitis.
        J Allergy Clin Immunol. 2010; 125: S103-S115
        • Gibson R.L.
        • Burns J.L.
        • Ramsey B.W.
        Pathophysiology and management of pulmonary infections in cystic fibrosis.
        Am J Respir Crit Care Med. 2003; 168: 918-951
        • Chinen J.
        • Shearer W.T.
        Secondary immunodeficiencies, including HIV infection.
        J Allergy Clin Immunol. 2010; 125: S195-S203
        • Oliveira J.B.
        • Fleisher T.A.
        Laboratory evaluation of primary immunodeficiencies.
        J Allergy Clin Immunol. 2010; 125: S297-S305
        • Carneiro-Sampaio M.M.
        • Grumach A.S.
        • Manissadjian A.
        Laboratory screening for the diagnosis of children with primary immunodeficiencies.
        J Investig Allergol Clin Immunol. 1991; 1: 195-200
        • Jeurissen A.
        • Moens L.
        • Raes M.
        • Wuyts G.
        • Willebrords L.
        • Sauer K.
        • et al.
        Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens.
        Clin Chem. 2007; 53: 505-510
        • Landesman S.H.
        • Schiffman G.
        Assessment of the antibody response to pneumococcal vaccine in high-risk populations.
        Rev Infect Dis. 1981; 3: S184-S197
        • Paris K.
        • Sorensen R.U.
        Assessment and clinical interpretation of polysaccharide antibody responses.
        Ann Allergy Asthma Immunol. 2007; 99: 462-464
        • Siber G.R.
        • Chang I.
        • Baker S.
        • Fernsten P.
        • O'Brien K.L.
        • Santosham M.
        • et al.
        Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
        Vaccine. 2007; 25: 3816-3826
        • Balloch A.
        • Licciardi P.V.
        • Tang M.L.
        Serotype-specific anti-pneumococcal IgG and immune competence: critical differences in interpretation criteria when different methods are used.
        J Clin Immunol. 2013; 33: 335-341
        • Whaley M.J.
        • Rose C.
        • Martinez J.
        • Laher G.
        • Sammons D.L.
        • Smith J.P.
        • et al.
        Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides.
        Clin Vaccine Immunol. 2010; 17: 862-869
        • Duplantier J.E.
        • Seyama K.
        • Day N.K.
        • Hitchcock R.
        • Nelson Jr., R.P.
        • Ochs H.D.
        • et al.
        Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome.
        Clin Immunol. 2001; 98: 313-318
        • Rubinstein A.
        • Mizrachi Y.
        • Bernstein L.
        • Shliozberg J.
        • Golodner M.
        • Liu G.Q.
        • et al.
        Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients.
        AIDS. 2000; 14: F55-F62
        • Bonilla F.A.
        Interpretation of lymphocyte proliferation tests.
        Ann Allergy Asthma Immunol. 2008; 101: 101-104
        • Stone K.D.
        • Feldman H.A.
        • Huisman C.
        • Howlett C.
        • Jabara H.H.
        • Bonilla F.A.
        Analysis of in vitro lymphocyte proliferation as a screening tool for cellular immunodeficiency.
        Clin Immunol. 2009; 131: 41-49
        • Fischer A.
        • Hacein-Bey-Abina S.
        • Cavazzana-Calvo M.
        Gene therapy for primary adaptive immune deficiencies.
        J Allergy Clin Immunol. 2011; 127: 1356-1359
        • Pessach I.M.
        • Notarangelo L.D.
        Gene therapy for primary immunodeficiencies: looking ahead, toward gene correction.
        J Allergy Clin Immunol. 2011; 127: 1344-1350
        • Anderson-Cohen M.
        • Holland S.M.
        • Kuhns D.B.
        • Fleisher T.A.
        • Ding L.
        • Brenner S.
        • et al.
        Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation.
        Clin Immunol. 2003; 109: 308-317
        • Andreu N.
        • Pujol-Moix N.
        • Martinez-Lostao L.
        • Oset M.
        • Muniz-Diaz E.
        • Estivill X.
        • et al.
        Wiskott-Aldrich syndrome in a female with skewed X-chromosome inactivation.
        Blood Cells Mol Dis. 2003; 31: 332-337
        • Lutskiy M.I.
        • Sasahara Y.
        • Kenney D.M.
        • Rosen F.S.
        • Remold-O'Donnell E.
        Wiskott-Aldrich syndrome in a female.
        Blood. 2002; 100: 2763-2768
        • Takada H.
        • Kanegane H.
        • Nomura A.
        • Yamamoto K.
        • Ihara K.
        • Takahashi Y.
        • et al.
        Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.
        Blood. 2004; 103: 185-187
        • de Saint Basile G.
        • Tabone M.D.
        • Durandy A.
        • Phan F.
        • Fischer A.
        • Le Deist F.
        CD40 ligand expression deficiency in a female carrier of the X-linked hyper-IgM syndrome as a result of X chromosome lyonization.
        Eur J Immunol. 1999; 29: 367-373
        • Erdos M.
        • Alapi K.
        • Marodi L.
        Retrospective diagnosis of X-linked hyper-IgM syndrome in a family with multiple deaths of affected males.
        Haematologica. 2007; 92: 281-282
        • Fried A.J.
        • Bonilla F.A.
        Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections.
        Clin Microbiol Rev. 2009; 22: 396-414
        • Griffith L.M.
        • Cowan M.J.
        • Notarangelo L.D.
        • Puck J.M.
        • Buckley R.H.
        • Candotti F.
        • et al.
        Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.
        J Allergy Clin Immunol. 2009; 124: 1152-1160.e12
        • Orange J.S.
        • Hossny E.M.
        • Weiler C.R.
        • Ballow M.
        • Berger M.
        • Bonilla F.A.
        • et al.
        Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
        J Allergy Clin Immunol. 2006; 117: S525-S553
        • Yong P.L.
        • Boyle J.
        • Ballow M.
        • Boyle M.
        • Berger M.
        • Bleesing J.
        • et al.
        Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology.
        Clin Immunol. 2010; 135: 255-263
        • Buckley R.H.
        B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review.
        J Allergy Clin Immunol. 2010; 125: 790-797
        • Horn J.
        • Thon V.
        • Bartonkova D.
        • Salzer U.
        • Warnatz K.
        • Schlesier M.
        • et al.
        Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy.
        Clin Immunol. 2007; 122: 156-162
        • Rachid R.
        • Bonilla F.A.
        The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature.
        J Allergy Clin Immunol. 2012; 129: 628-634
        • Rachid R.
        • Castells M.
        • Cunningham-Rundles C.
        • Bonilla F.A.
        Association of anti-IgA antibodies with adverse reactions to gamma-globulin infusion.
        J Allergy Clin Immunol. 2011; 128: 228-230.e1
        • Cunningham-Rundles C.
        How I treat common variable immune deficiency.
        Blood. 2010; 116: 7-15
        • Menis M.
        • Sridhar G.
        • Selvam N.
        • Ovanesov M.V.
        • Divan H.A.
        • Liang Y.
        • et al.
        Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011.
        Am J Hematol. 2013; 88: 1035-1040
        • Sridhar G.
        • Ekezue B.F.
        • Izurieta H.S.
        • Selvam N.
        • Ovanesov M.V.
        • Divan H.A.
        • et al.
        Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012.
        Transfusion. 2014; 54: 2553-2565
        • Berard R.
        • Whittemore B.
        • Scuccimarri R.
        Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases.
        Pediatr Rheumatol Online J. 2012; 10: 10
        • di Carlo I.
        • Fisichella P.
        • Russello D.
        • Puleo S.
        • Latteri F.
        Catheter fracture and cardiac migration: a rare complication of totally implantable venous devices.
        J Surg Oncol. 2000; 73: 172-173
        • Torgerson T.R.
        Overview of routes of IgG administration.
        J Clin Immunol. 2013; 33: S87-S89
        • Chen Y.
        • Stirling R.G.
        • Paul E.
        • Hore-Lacy F.
        • Thompson B.R.
        • Douglass J.A.
        Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies.
        J Allergy Clin Immunol. 2011; 127: 1414-1417
        • Lucas M.
        • Lee M.
        • Lortan J.
        • Lopez-Granados E.
        • Misbah S.
        • Chapel H.
        Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.
        J Allergy Clin Immunol. 2010; 125: 1354-1360.e4
        • Kuruvilla M.
        • de la Morena M.T.
        Antibiotic prophylaxis in primary immune deficiency disorders.
        J Allergy Clin Immunol Pract. 2013; 1: 573-582
        • Leach A.J.
        • Morris P.S.
        Antibiotics for the prevention of acute and chronic suppurative otitis media in children.
        Cochrane Database Syst Rev. 2006; : CD004401
        • Gafter-Gvili A.
        • Fraser A.
        • Paul M.
        • Vidal L.
        • Lawrie T.A.
        • van de Wetering M.D.
        • et al.
        Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.
        Cochrane Database Syst Rev. 2012; 1: CD004386
        • Wood P.
        • Stanworth S.
        • Burton J.
        • Jones A.
        • Peckham D.G.
        • Green T.
        • et al.
        Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review.
        Clin Exp Immunol. 2007; 149: 410-423
        • Stiehm E.R.
        • Chapel H.M.
        Conventional therapy of primary immunodeficiency diseases.
        in: Ochs H.D. Smith C.I.E. Puck J.M. Primary immunodeficiency diseases: a molecular and genetic approach. 2nd ed. Oxford University Press, Oxford2007: 656-668
        • Ovesen T.
        • Kragelund J.R.
        • Jensen J.M.
        • Thiel S.
        • Veirum J.E.
        Immunodeficiencies in children with chronic post tympanic otorrhoea.
        Dan Med Bull. 2011; 58: A4282
        • Criddle M.W.
        • Stinson A.
        • Savliwala M.
        • Coticchia J.
        Pediatric chronic rhinosinusitis: a retrospective review.
        Am J Otolaryngol. 2008; 29: 372-378
        • Griffith L.M.
        • Cowan M.J.
        • Kohn D.B.
        • Notarangelo L.D.
        • Puck J.M.
        • Schultz K.R.
        • et al.
        Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs.
        J Allergy Clin Immunol. 2008; 122: 1087-1096
        • Kang H.J.
        • Bartholomae C.C.
        • Paruzynski A.
        • Arens A.
        • Kim S.
        • Yu S.S.
        • et al.
        Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial.
        Mol Ther. 2011; 19: 2092-2101
        • Martinez C.A.
        • Shah S.
        • Shearer W.T.
        • Rosenblatt H.M.
        • Paul M.E.
        • Chinen J.
        • et al.
        Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease.
        J Allergy Clin Immunol. 2012; 129: 176-183
        • Hacein-Bey-Abina S.
        • Garrigue A.
        • Wang G.P.
        • Soulier J.
        • Lim A.
        • Morillon E.
        • et al.
        Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
        J Clin Invest. 2008; 118: 3132-3142
        • Ferrua F.
        • Brigida I.
        • Aiuti A.
        Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
        Curr Opin Allergy Clin Immunol. 2010; 10: 551-556
        • Boztug K.
        • Schmidt M.
        • Schwarzer A.
        • Banerjee P.P.
        • Diez I.A.
        • Dewey R.A.
        • et al.
        Stem-cell gene therapy for the Wiskott-Aldrich syndrome.
        N Engl J Med. 2010; 363: 1918-1927
        • Chinn I.K.
        • Markert M.L.
        Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly.
        J Allergy Clin Immunol. 2011; 127: 1351-1355
        • Brown L.
        • Xu-Bayford J.
        • Allwood Z.
        • Slatter M.
        • Cant A.
        • Davies E.G.
        • et al.
        Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening.
        Blood. 2011; 117: 3243-3246
        • Chan A.
        • Scalchunes C.
        • Boyle M.
        • Puck J.M.
        Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey.
        Clin Immunol. 2011; 138: 3-8
        • Chan K.
        • Davis J.
        • Pai S.Y.
        • Bonilla F.A.
        • Puck J.M.
        • Apkon M.
        A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
        Mol Genet Metab. 2011; 104: 383-389
        • la Marca G.
        • Canessa C.
        • Giocaliere E.
        • Romano F.
        • Duse M.
        • Malvagia S.
        • et al.
        Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency.
        J Allergy Clin Immunol. 2013; 131: 1604-1610
        • Lindholm P.F.
        • Annen K.
        • Ramsey G.
        Approaches to minimize infection risk in blood banking and transfusion practice.
        Infect Disord Drug Targets. 2011; 11: 45-56
        • Buckley R.H.
        • Ballas Z.
        • Ballow M.
        • Blaese M.
        • Bonilla F.A.
        • Conley M.E.
        • et al.
        Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts.
        J Allergy Clin Immunol. 2014; 133: 961-966
        • Active and passive immunization
        Immunization in special clinical circumstances: immunocompromised children.
        in: Pickering L.K. Red Book: 2012 Report of the Committee on Infectious Diseases. 29nd ed. American Academy of Pediatrics, Elk Grove Village (IL)2012: 74-90
        • Patel N.C.
        • Hertel P.M.
        • Estes M.K.
        • de la Morena M.
        • Petru A.M.
        • Noroski L.M.
        • et al.
        Vaccine-acquired rotavirus in infants with severe combined immunodeficiency.
        N Engl J Med. 2010; 362: 314-319
        • Moylett E.H.
        • Wasan A.N.
        • Noroski L.M.
        • Shearer W.T.
        Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity.
        Clin Immunol. 2004; 112: 106-112
        • Perez E.E.
        • Bokszczanin A.
        • McDonald-McGinn D.
        • Zackai E.H.
        • Sullivan K.E.
        Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
        Pediatrics. 2003; 112: e325
        • Kroger A.T.
        • Atkinson W.L.
        • Marcuse E.K.
        • Pickering L.K.
        Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2006; 55: 1-48
        • Junker A.K.
        • Bonilla F.A.
        • Sullivan K.E.
        How to flee the flu.
        Clin Immunol. 2004; 112: 219-220
        • Atkinson T.P.
        Immune deficiency and autoimmunity.
        Curr Opin Rheumatol. 2012; 24: 515-521
        • Salavoura K.
        • Kolialexi A.
        • Tsangaris G.
        • Mavrou A.
        Development of cancer in patients with primary immunodeficiencies.
        Anticancer Res. 2008; 28: 1263-1269
        • Aloj G.
        • Giardino G.
        • Valentino L.
        • Maio F.
        • Gallo V.
        • Esposito T.
        • et al.
        Severe combined immunodeficiences: new and old scenarios.
        Int Rev Immunol. 2012; 31: 43-65
        • Sponzilli I.
        • Notarangelo L.D.
        Severe combined immunodeficiency (SCID): from molecular basis to clinical management.
        Acta Biomed. 2011; 82: 5-13
        • Dadi H.K.
        • Simon A.J.
        • Roifman C.M.
        Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency.
        N Engl J Med. 2003; 349: 1821-1828
        • Shiow L.R.
        • Roadcap D.W.
        • Paris K.
        • Watson S.R.
        • Grigorova I.L.
        • Lebet T.
        • et al.
        The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency.
        Nat Immunol. 2008; 9: 1307-1315
        • Montiel-Equihua C.A.
        • Thrasher A.J.
        • Gaspar H.B.
        Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
        Curr Gene Ther. 2012; 12: 57-65
        • Sauer A.V.
        • Aiuti A.
        New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy.
        Curr Opin Allergy Clin Immunol. 2009; 9: 496-502
        • Henderson L.A.
        • Frugoni F.
        • Hopkins G.
        • Al-Herz W.
        • Weinacht K.
        • Comeau A.M.
        • et al.
        First reported case of Omenn syndrome in a patient with reticular dysgenesis.
        J Allergy Clin Immunol. 2013; 131 (e1-3): 1227-1230
        • Lagresle-Peyrou C.
        • Six E.M.
        • Picard C.
        • Rieux-Laucat F.
        • Michel V.
        • Ditadi A.
        • et al.
        Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness.
        Nat Genet. 2009; 41: 106-111
        • Pannicke U.
        • Honig M.
        • Hess I.
        • Friesen C.
        • Holzmann K.
        • Rump E.M.
        • et al.
        Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2.
        Nat Genet. 2009; 41: 101-105
        • Ege M.
        • Ma Y.
        • Manfras B.
        • Kalwak K.
        • Lu H.
        • Lieber M.R.
        • et al.
        Omenn syndrome due to ARTEMIS mutations.
        Blood. 2005; 105: 4179-4186
        • Moshous D.
        • Pannetier C.
        • Chasseval Rd R.
        • Deist Fl
        • Cavazzana-Calvo M.
        • Romana S.
        • et al.
        Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis.
        J Clin Invest. 2003; 111: 381-387
        • Buck D.
        • Malivert L.
        • de Chasseval R.
        • Barraud A.
        • Fondaneche M.C.
        • Sanal O.
        • et al.
        Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly.
        Cell. 2006; 124: 287-299
        • Du L.
        • Peng R.
        • Bjorkman A.
        • Filipe de Miranda N.
        • Rosner C.
        • Kotnis A.
        • et al.
        Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis.
        J Exp Med. 2012; 209: 291-305
        • van der Burg M.
        • Ijspeert H.
        • Verkaik N.S.
        • Turul T.
        • Wiegant W.W.
        • Morotomi-Yano K.
        • et al.
        A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining.
        J Clin Invest. 2009; 119: 91-98
        • Chistiakov D.A.
        Ligase IV syndrome.
        Adv Exp Med Biol. 2010; 685: 175-185
        • van der Burg M.
        • van Veelen L.R.
        • Verkaik N.S.
        • Wiegant W.W.
        • Hartwig N.G.
        • Barendregt B.H.
        • et al.
        A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation.
        J Clin Invest. 2006; 116: 137-145
        • Kutukculer N.
        • Gulez N.
        • Karaca N.E.
        • Aksu G.
        • Berdeli A.
        Novel mutations and diverse clinical phenotypes in recombinase-activating gene 1 deficiency.
        Ital J Pediatr. 2012; 38: 8
        • Pasic S.
        • Djuricic S.
        • Ristic G.
        • Slavkovic B.
        Recombinase-activating gene 1 immunodeficiency: different immunological phenotypes in three siblings.
        Acta Paediatr. 2009; 98: 1062-1064
        • De Ravin S.S.
        • Cowen E.W.
        • Zarember K.A.
        • Whiting-Theobald N.L.
        • Kuhns D.B.
        • Sandler N.G.
        • et al.
        Hypomorphic Rag mutations can cause destructive midline granulomatous disease.
        Blood. 2010; 116: 1263-1271
        • de Villartay J.P.
        V(D)J recombination deficiencies.
        Adv Exp Med Biol. 2009; 650: 46-58
        • Kawai T.
        • Saito M.
        • Nishikomori R.
        • Yasumi T.
        • Izawa K.
        • Murakami T.
        • et al.
        Multiple reversions of an IL2RG mutation restore T cell function in an X-linked severe combined immunodeficiency patient.
        J Clin Immunol. 2012; 32: 690-697
        • Recher M.
        • Berglund L.J.
        • Avery D.T.
        • Cowan M.J.
        • Gennery A.R.
        • Smart J.
        • et al.
        IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo.
        Blood. 2011; 118: 6824-6835
        • Poliani P.L.
        • Facchetti F.
        • Ravanini M.
        • Gennery A.R.
        • Villa A.
        • Roifman C.M.
        • et al.
        Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome.
        Blood. 2009; 114: 105-108
        • Speckmann C.
        • Pannicke U.
        • Wiech E.
        • Schwarz K.
        • Fisch P.
        • Friedrich W.
        • et al.
        Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency.
        Blood. 2008; 112: 4090-4097
        • Casanova J.L.
        • Holland S.M.
        • Notarangelo L.D.
        Inborn errors of human JAKs and STATs.
        Immunity. 2012; 36: 515-528
        • Caudy A.A.
        • Reddy S.T.
        • Chatila T.
        • Atkinson J.P.
        • Verbsky J.W.
        CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes.
        J Allergy Clin Immunol. 2007; 119: 482-487
        • Roifman C.M.
        Human IL-2 receptor alpha chain deficiency.
        Pediatr Res. 2000; 48: 6-11
        • Rieux-Laucat F.
        • Hivroz C.
        • Lim A.
        • Mateo V.
        • Pellier I.
        • Selz F.
        • et al.
        Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency.
        N Engl J Med. 2006; 354: 1913-1921
        • Fischer A.
        • de Saint Basile G.
        • Le Deist F.
        CD3 deficiencies.
        Curr Opin Allergy Clin Immunol. 2005; 5: 491-495
        • de Saint Basile G.
        • Geissmann F.
        • Flori E.
        • Uring-Lambert B.
        • Soudais C.
        • Cavazzana-Calvo M.
        • et al.
        Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3.
        J Clin Invest. 2004; 114: 1512-1517
        • Yu G.P.
        • Nadeau K.C.
        • Berk D.R.
        • de Saint Basile G.
        • Lambert N.
        • Knapnougel P.
        • et al.
        Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCID.
        Pediatr Transplant. 2011; 15: 733-741
        • Roberts J.L.
        • Buckley R.H.
        • Luo B.
        • Pei J.
        • Lapidus A.
        • Peri S.
        • et al.
        CD45-deficient severe combined immunodeficiency caused by uniparental disomy.
        Proc Natl Acad Sci U S A. 2012; 109: 10456-10461
        • Tchilian E.Z.
        • Wallace D.L.
        • Wells R.S.
        • Flower D.R.
        • Morgan G.
        • Beverley P.C.
        A deletion in the gene encoding the CD45 antigen in a patient with SCID.
        J Immunol. 2001; 166: 1308-1313
        • Giliani S.
        • Bonfim C.
        • de Saint Basile G.
        • Lanzi G.
        • Brousse N.
        • Koliski A.
        • et al.
        Omenn syndrome in an infant with IL7RA gene mutation.
        J Pediatr. 2006; 148: 272-274
        • Griffith L.M.
        • Cowan M.J.
        • Notarangelo L.D.
        • Kohn D.B.
        • Puck J.M.
        • Pai S.Y.
        • et al.
        Primary Immune Deficiency Treatment Consortium (PIDTC) report.
        J Allergy Clin Immunol. 2014; 133: 335-347
        • Shearer W.T.
        • Dunn E.
        • Notarangelo L.D.
        • Dvorak C.C.
        • Puck J.M.
        • Logan B.R.
        • et al.
        Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience.
        J Allergy Clin Immunol. 2014; 133: 1092-1098
        • Lev A.
        • Simon A.J.
        • Trakhtenbrot L.
        • Goldstein I.
        • Nagar M.
        • Stepensky P.
        • et al.
        Characterizing T Cells in SCID Patients Presenting with Reactive or Residual T Lymphocytes.
        Clin Dev Immunol. 2012; 2012: 261470
        • Zubakov D.
        • Liu F.
        • van Zelm M.C.
        • Vermeulen J.
        • Oostra B.A.
        • van Duijn C.M.
        • et al.
        Estimating human age from T-cell DNA rearrangements.
        Curr Biol. 2010; 20: R970-R971
        • Buckley R.H.
        Variable phenotypic expression of mutations in genes of the immune system.
        J Clin Invest. 2005; 115: 2974-2976
        • Gennery A.R.
        • Slatter M.A.
        • Rice J.
        • Hoefsloot L.H.
        • Barge D.
        • McLean-Tooke A.
        • et al.
        Mutations in CHD7 in patients with CHARGE syndrome cause T-B + natural killer cell + severe combined immune deficiency and may cause Omenn-like syndrome.
        Clin Exp Immunol. 2008; 153: 75-80
        • Villa A.
        • Notarangelo L.D.
        • Roifman C.M.
        Omenn syndrome: inflammation in leaky severe combined immunodeficiency.
        J Allergy Clin Immunol. 2008; 122: 1082-1086
        • Felgentreff K.
        • Perez-Becker R.
        • Speckmann C.
        • Schwarz K.
        • Kalwak K.
        • Markelj G.
        • et al.
        Clinical and immunological manifestations of patients with atypical severe combined immunodeficiency.
        Clin Immunol. 2011; 141: 73-82
        • Sillevis Smitt J.H.
        • Kuijpers T.W.
        Cutaneous manifestations of primary immunodeficiency.
        Curr Opin Pediatr. 2013; 25: 492-497
        • Yu X.
        • Almeida J.R.
        • Darko S.
        • van der Burg M.
        • DeRavin S.S.
        • Malech H.
        • et al.
        Human syndromes of immunodeficiency and dysregulation are characterized by distinct defects in T-cell receptor repertoire development.
        J Allergy Clin Immunol. 2014; 133: 1109-1115
        • Roifman C.M.
        • Gu Y.
        • Cohen A.
        Mutations in the RNA component of RNase mitochondrial RNA processing might cause Omenn syndrome.
        J Allergy Clin Immunol. 2006; 117: 897-903
        • Chan W.Y.
        • Roberts R.L.
        • Moore T.B.
        • Stiehm E.R.
        Cord blood transplants for SCID: better b-cell engraftment?.
        J Pediatr Hematol Oncol. 2013; 35: e14-e18
        • Cuvelier G.D.
        • Schultz K.R.
        • Davis J.
        • Hirschfeld A.F.
        • Junker A.K.
        • Tan R.
        • et al.
        Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency.
        Clin Immunol. 2009; 131: 179-188
        • Khanna N.
        • Widmer A.F.
        • Decker M.
        • Steffen I.
        • Halter J.
        • Heim D.
        • et al.
        Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature.
        Clin Infect Dis. 2008; 46: 402-412
        • Honig M.
        • Schulz A.
        • Friedrich W.
        Hematopoietic stem cell transplantation for severe combined immunodeficiency.
        Klin Padiatr. 2011; 223: 320-325
        • Booth C.
        • Gaspar H.B.
        Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).
        Biologics. 2009; 3: 349-358
        • Gaspar H.B.
        • Cooray S.
        • Gilmour K.C.
        • Parsley K.L.
        • Zhang F.
        • Adams S.
        • et al.
        Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
        Sci Transl Med. 2011; 3: 97ra80
        • Myers L.A.
        • Patel D.D.
        • Puck J.M.
        • Buckley R.H.
        Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival.
        Blood. 2002; 99: 872-878
        • Buckley R.H.
        • Schiff S.E.
        • Schiff R.I.
        • Markert L.
        • Williams L.W.
        • Roberts J.L.
        • et al.
        Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.
        N Engl J Med. 1999; 340: 508-516
        • Aiuti A.
        • Cattaneo F.
        • Galimberti S.
        • Benninghoff U.
        • Cassani B.
        • Callegaro L.
        • et al.
        Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
        N Engl J Med. 2009; 360: 447-458
        • Kohn D.B.
        Update on gene therapy for immunodeficiencies.
        Clin Immunol. 2010; 135: 247-254
        • Howe S.J.
        • Mansour M.R.
        • Schwarzwaelder K.
        • Bartholomae C.
        • Hubank M.
        • Kempski H.
        • et al.
        Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
        J Clin Invest. 2008; 118: 3143-3150
        • Cattoglio C.
        • Pellin D.
        • Rizzi E.
        • Maruggi G.
        • Corti G.
        • Miselli F.
        • et al.
        High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors.
        Blood. 2010; 116: 5507-5517
        • Feske S.
        • Gwack Y.
        • Prakriya M.
        • Srikanth S.
        • Puppel S.H.
        • Tanasa B.
        • et al.
        A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function.
        Nature. 2006; 441: 179-185
        • Li F.Y.
        • Chaigne-Delalande B.
        • Kanellopoulou C.
        • Davis J.C.
        • Matthews H.F.
        • Douek D.C.
        • et al.
        Second messenger role for Mg2+ revealed by human T-cell immunodeficiency.
        Nature. 2011; 475: 471-476
        • McCarl C.A.
        • Picard C.
        • Khalil S.
        • Kawasaki T.
        • Rother J.
        • Papolos A.
        • et al.
        ORAI1 deficiency and lack of store-operated Ca2+ entry cause immunodeficiency, myopathy, and ectodermal dysplasia.
        J Allergy Clin Immunol. 2009; 124: 1311-1318.e7
        • Picard C.
        • McCarl C.A.
        • Papolos A.
        • Khalil S.
        • Luthy K.
        • Hivroz C.
        • et al.
        STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity.
        N Engl J Med. 2009; 360: 1971-1980
        • Snow A.L.
        • Xiao W.
        • Stinson J.R.
        • Lu W.
        • Chaigne-Delalande B.
        • Zheng L.
        • et al.
        Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.
        J Exp Med. 2012; 209: 2247-2261
        • Stepensky P.
        • Keller B.
        • Buchta M.
        • Kienzler A.K.
        • Elpeleg O.
        • Somech R.
        • et al.
        Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects.
        J Allergy Clin Immunol. 2013; 131: 477-485.e1
        • Pieper K.
        • Grimbacher B.
        • Eibel H.
        B-cell biology and development.
        J Allergy Clin Immunol. 2013; 131: 959-971
        • van Montfrans J.M.
        • Hoepelman A.I.
        • Otto S.
        • van Gijn M.
        • van de Corput L.
        • de Weger R.A.
        • et al.
        CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.
        J Allergy Clin Immunol. 2012; 129: 787-793.e6
        • de la Calle-Martin O.
        • Hernandez M.
        • Ordi J.
        • Casamitjana N.
        • Arostegui J.I.
        • Caragol I.
        • et al.
        Familial CD8 deficiency due to a mutation in the CD8 alpha gene.
        J Clin Invest. 2001; 108: 117-123
        • Kuehn H.S.
        • Ouyang W.
        • Lo B.
        • Deenick E.K.
        • Niemela J.E.
        • Avery D.T.
        • et al.
        Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
        Science. 2014; 345: 1623-1627
        • Schubert D.
        • Bode C.
        • Kenefeck R.
        • Hou T.Z.
        • Wing J.B.
        • Kennedy A.
        • et al.
        Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
        Nat Med. 2014; 20: 1410-1416
        • Martin E.
        • Palmic N.
        • Sanquer S.
        • Lenoir C.
        • Hauck F.
        • Mongellaz C.
        • et al.
        CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation.
        Nature. 2014; 510: 288-292
        • Markert M.L.
        • Marques J.G.
        • Neven B.
        • Devlin B.H.
        • McCarthy E.A.
        • Chinn I.K.
        • et al.
        First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases.
        Blood. 2011; 117: 688-696
        • Pignata C.
        • Fusco A.
        • Amorosi S.
        Human clinical phenotype associated with FOXN1 mutations.
        Adv Exp Med Biol. 2009; 665: 195-206
        • Vigliano I.
        • Gorrese M.
        • Fusco A.
        • Vitiello L.
        • Amorosi S.
        • Panico L.
        • et al.
        FOXN1 mutation abrogates prenatal T-cell development in humans.
        J Med Genet. 2011; 48: 413-416
        • Goldman F.D.
        • Gurel Z.
        • Al-Zubeidi D.
        • Fried A.J.
        • Icardi M.
        • Song C.
        • et al.
        Congenital pancytopenia and absence of B lymphocytes in a neonate with a mutation in the Ikaros gene.
        Pediatr Blood Cancer. 2012; 58: 591-597
        • Kotlarz D.
        • Zietara N.
        • Uzel G.
        • Weidemann T.
        • Braun C.J.
        • Diestelhorst J.
        • et al.
        Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome.
        J Exp Med. 2013; 210: 433-443
        • Linka R.M.
        • Risse S.L.
        • Bienemann K.
        • Werner M.
        • Linka Y.
        • Krux F.
        • et al.
        Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases.
        Leukemia. 2012; 26: 963-971
        • Hussain A.
        • Yu L.
        • Faryal R.
        • Mohammad D.K.
        • Mohamed A.J.
        • Smith C.I.
        TEC family kinases in health and disease—loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.
        FEBS J. 2011; 278: 2001-2010
        • Huck K.
        • Feyen O.
        • Niehues T.
        • Ruschendorf F.
        • Hubner N.
        • Laws H.J.
        • et al.
        Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation.
        J Clin Invest. 2009; 119: 1350-1358
        • Stepensky P.
        • Weintraub M.
        • Yanir A.
        • Revel-Vilk S.
        • Krux F.
        • Huck K.
        • et al.
        IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
        Haematologica. 2011; 96: 472-476
        • Zimmer J.
        • Andres E.
        Comments on type I bare lymphocyte syndrome.
        Immunol Lett. 2012; 143: 218-219
        • Zimmer J.
        • Andres E.
        • Donato L.
        • Hanau D.
        • Hentges F.
        • de la Salle H.
        Clinical and immunological aspects of HLA class I deficiency.
        QJM. 2005; 98: 719-727
        • Gokturk B.
        • Artac H.
        • van Eggermond M.J.
        • van den Elsen P.
        • Reisli I.
        Type III bare lymphocyte syndrome associated with a novel RFXAP mutation: a case report.
        Int J Immunogenet. 2012; 39: 362-364
        • Krawczyk M.
        • Reith W.
        Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease.
        Tissue Antigens. 2006; 67: 183-197
        • Ouederni M.
        • Vincent Q.B.
        • Frange P.
        • Touzot F.
        • Scerra S.
        • Bejaoui M.
        • et al.
        Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients.
        Blood. 2011; 118: 5108-5118
        • Siepermann M.
        • Gudowius S.
        • Beltz K.
        • Strier U.
        • Feyen O.
        • Troeger A.
        • et al.
        MHC class II deficiency cured by unrelated mismatched umbilical cord blood transplantation: case report and review of 68 cases in the literature.
        Pediatr Transplant. 2011; 15: E80-E86
        • Villard J.
        • Masternak K.
        • Lisowska-Grospierre B.
        • Fischer A.
        • Reith W.
        MHC class II deficiency: a disease of gene regulation.
        Medicine (Baltimore). 2001; 80: 405-418
        • Somech R.
        • Lev A.
        • Grisaru-Soen G.
        • Shiran S.I.
        • Simon A.J.
        • Grunebaum E.
        Purine nucleoside phosphorylase deficiency presenting as severe combined immune deficiency.
        Immunol Res. 2013; 56: 150-154
        • Walker P.L.
        • Corrigan A.
        • Arenas M.
        • Escuredo E.
        • Fairbanks L.
        • Marinaki A.
        Purine nucleoside phosphorylase deficiency: a mutation update.
        Nucleosides Nucleotides Nucleic Acids. 2011; 30: 1243-1247
        • Stray-Pedersen A.
        • Backe P.H.
        • Sorte H.S.
        • Morkrid L.
        • Chokshi N.Y.
        • Erichsen H.C.
        • et al.
        PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia.
        Am J Hum Genet. 2014; 95: 96-107
        • Pachlopnik Schmid J.
        • Lemoine R.
        • Nehme N.
        • Cormier-Daire V.
        • Revy P.
        • Debeurme F.
        • et al.
        Polymerase epsilon1 mutation in a human syndrome with facial dysmorphism, immunodeficiency, livedo, and short stature (“FILS syndrome”).
        J Exp Med. 2012; 209: 2323-2330
        • Borzutzky A.
        • Crompton B.
        • Bergmann A.K.
        • Giliani S.
        • Baxi S.
        • Martin M.
        • et al.
        Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter.
        Clin Immunol. 2009; 133: 287-294
        • Crequer A.
        • Picard C.
        • Patin E.
        • D'Amico A.
        • Abhyankar A.
        • Munzer M.
        • et al.
        Inherited MST1 deficiency underlies susceptibility to EV-HPV infections.
        PLoS One. 2012; 7: e44010
        • Kanai T.
        • Jenks J.
        • Nadeau K.C.
        The STAT5b pathway defect and autoimmunity.
        Front Immunol. 2012; 3: 234
        • Nadeau K.
        • Hwa V.
        • Rosenfeld R.G.
        STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease.
        J Pediatr. 2011; 158: 701-708
        • Scaglia P.A.
        • Martinez A.S.
        • Feigerlova E.
        • Bezrodnik L.
        • Gaillard M.I.
        • Di Giovanni D.
        • et al.
        A novel missense mutation in the SH2 domain of the STAT5B gene results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease.
        J Clin Endocrinol Metab. 2012; 97: E830-E839
        • Ram G.
        • Chinen J.
        Infections and immunodeficiency in Down syndrome.
        Clin Exp Immunol. 2011; 164: 9-16
        • Chakraborty P.K.
        • Schmitz-Abe K.
        • Kennedy E.K.
        • Mamady H.
        • Naas T.
        • Durie D.
        • et al.
        Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD).
        Blood. 2014; 124: 2867-2871
        • Karaca E.
        • Karakoc-Aydiner E.
        • Bayrak O.F.
        • Keles S.
        • Sevli S.
        • Barlan I.B.
        • et al.
        Identification of a novel mutation in ZAP70 and prenatal diagnosis in a Turkish family with severe combined immunodeficiency disorder.
        Gene. 2013; 512: 189-193
        • Picard C.
        • Dogniaux S.
        • Chemin K.
        • Maciorowski Z.
        • Lim A.
        • Mazerolles F.
        • et al.
        Hypomorphic mutation of ZAP70 in human results in a late onset immunodeficiency and no autoimmunity.
        Eur J Immunol. 2009; 39: 1966-1976
        • Turul T.
        • Tezcan I.
        • Artac H.
        • de Bruin-Versteeg S.
        • Barendregt B.H.
        • Reisli I.
        • et al.
        Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency.
        Eur J Pediatr. 2009; 168: 87-93
        • Qamar N.
        • Fuleihan R.L.
        The hyper IgM syndromes.
        Clin Rev Allergy Immunol. 2014; 46: 120-130
        • Kemp A.
        Use of the term ‘hyper IgM syndrome’.
        J Paediatr Child Health. 2008; 44: 155-156
        • Touw I.P.
        • Bontenbal M.
        Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?.
        J Natl Cancer Inst. 2007; 99: 183-186
        • Hadzic N.
        • Pagliuca A.
        • Rela M.
        • Portmann B.
        • Jones A.
        • Veys P.
        • et al.
        Correction of the hyper-IgM syndrome after liver and bone marrow transplantation.
        N Engl J Med. 2000; 342: 320-324
        • Martinez Ibanez V.
        • Espanol T.
        • Matamoros N.
        • Iglesias J.
        • Allende H.
        • Lucaya T.
        • et al.
        Relapse of sclerosing cholangitis after liver transplant in patients with hyper-Ig M syndrome.
        Transplant Proc. 1997; 29: 432-433
        • Al-Dhekri H.
        • Al-Sum Z.
        • Al-Saud B.
        • Al-Mousa H.
        • Ayas M.
        • Al-Muhsen S.
        • et al.
        Successful outcome in two patients with CD40 deficiency treated with allogeneic HCST.
        Clin Immunol. 2012; 143: 96-98
        • Jain A.
        • Kovacs J.A.
        • Nelson D.L.
        • Migueles S.A.
        • Pittaluga S.
        • Fanslow W.
        • et al.
        Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand.
        Blood. 2011; 118: 3811-3817
        • Albert M.H.
        • Notarangelo L.D.
        • Ochs H.D.
        Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome.
        Curr Opin Hematol. 2011; 18: 42-48
        • Catucci M.
        • Castiello M.C.
        • Pala F.
        • Bosticardo M.
        • Villa A.
        Autoimmunity in Wiskott-Aldrich syndrome: an unsolved enigma.
        Front Immunol. 2012; 3: 209
        • Du S.
        • Scuderi R.
        • Malicki D.M.
        • Willert J.
        • Bastian J.
        • Weidner N.
        Hodgkin's and non-Hodgkin's lymphomas occurring in two brothers with Wiskott-Aldrich syndrome and review of the literature.
        Pediatr Dev Pathol. 2011; 14: 64-70
        • Tran H.
        • Nourse J.
        • Hall S.
        • Green M.
        • Griffiths L.
        • Gandhi M.K.
        Immunodeficiency-associated lymphomas.
        Blood Rev. 2008; 22: 261-281
        • Albert M.H.
        • Bittner T.C.
        • Nonoyama S.
        • Notarangelo L.D.
        • Burns S.
        • Imai K.
        • et al.
        X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.
        Blood. 2010; 115: 3231-3238
        • Beel K.
        • Cotter M.M.
        • Blatny J.
        • Bond J.
        • Lucas G.
        • Green F.
        • et al.
        A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott-Aldrich syndrome gene.
        Br J Haematol. 2009; 144: 120-126
        • Westerberg L.S.
        • Meelu P.
        • Baptista M.
        • Eston M.A.
        • Adamovich D.A.
        • Cotta-de-Almeida V.
        • et al.
        Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes.
        J Exp Med. 2010; 207: 1145-1152
        • Nurden A.
        • Nurden P.
        Advances in our understanding of the molecular basis of disorders of platelet function.
        J Thromb Haemost. 2011; 9: 76-91
        • Ochs H.D.
        The Wiskott-Aldrich syndrome.
        Isr Med Assoc J. 2002; 4: 379-384
        • Ochs H.D.
        • Filipovich A.H.
        • Veys P.
        • Cowan M.J.
        • Kapoor N.
        Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment.
        Biol Blood Marrow Transplant. 2009; 15: 84-90
        • Ozsahin H.
        • Cavazzana-Calvo M.
        • Notarangelo L.D.
        • Schulz A.
        • Thrasher A.J.
        • Mazzolari E.
        • et al.
        Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation.
        Blood. 2008; 111: 439-445
        • Moratto D.
        • Giliani S.
        • Bonfim C.
        • Mazzolari E.
        • Fischer A.
        • Ochs H.D.
        • et al.
        Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study.
        Blood. 2011; 118: 1675-1684
        • Micol R.
        • Ben Slama L.
        • Suarez F.
        • Le Mignot L.
        • Beaute J.
        • Mahlaoui N.
        • et al.
        Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype.
        J Allergy Clin Immunol. 2011; 128: 382-389.e1
        • McGrath-Morrow S.A.
        • Gower W.A.
        • Rothblum-Oviatt C.
        • Brody A.S.
        • Langston C.
        • Fan L.L.
        • et al.
        Evaluation and management of pulmonary disease in ataxia-telangiectasia.
        Pediatr Pulmonol. 2010; 45: 847-859
        • Hagemeier S.R.
        • Barlow E.A.
        • Meng Q.
        • Kenney S.C.
        The cellular ataxia telangiectasia-mutated kinase promotes Epstein-Barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli.
        J Virol. 2012; 86: 13360-13370
        • Kulinski J.M.
        • Leonardo S.M.
        • Mounce B.C.
        • Malherbe L.
        • Gauld S.B.
        • Tarakanova V.L.
        Ataxia telangiectasia mutated kinase controls chronic gammaherpesvirus infection.
        J Virol. 2012; 86: 12826-12837
        • Stray-Pedersen A.
        • Jonsson T.
        • Heiberg A.
        • Lindman C.R.
        • Widing E.
        • Aaberge I.S.
        • et al.
        The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents.
        Clin Exp Immunol. 2004; 137: 179-186
        • Antoccia A.
        • Kobayashi J.
        • Tauchi H.
        • Matsuura S.
        • Komatsu K.
        Nijmegen breakage syndrome and functions of the responsible protein, NBS1.
        Genome Dyn. 2006; 1: 191-205
        • Chrzanowska K.H.
        • Gregorek H.
        • Dembowska-Baginska B.
        • Kalina M.A.
        • Digweed M.
        Nijmegen breakage syndrome (NBS).
        Orphanet J Rare Dis. 2012; 7: 13
        • Kondratenko I.
        • Paschenko O.
        • Polyakov A.
        • Bologov A.
        Nijmegen breakage syndrome.
        Adv Exp Med Biol. 2007; 601: 61-67
        • Soza S.
        • Leva V.
        • Vago R.
        • Ferrari G.
        • Mazzini G.
        • Biamonti G.
        • et al.
        DNA ligase I deficiency leads to replication-dependent DNA damage and impacts cell morphology without blocking cell cycle progression.
        Mol Cell Biol. 2009; 29: 2032-2041
        • Fernet M.
        • Gribaa M.
        • Salih M.A.
        • Seidahmed M.Z.
        • Hall J.
        • Koenig M.
        Identification and functional consequences of a novel MRE11 mutation affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like disorder.
        Hum Mol Genet. 2005; 14: 307-318
        • Oba D.
        • Hayashi M.
        • Minamitani M.
        • Hamano S.
        • Uchisaka N.
        • Kikuchi A.
        • et al.
        Autopsy study of cerebellar degeneration in siblings with ataxia-telangiectasia-like disorder.
        Acta Neuropathol. 2010; 119: 513-520
        • Amor-Gueret M.
        Bloom syndrome, genomic instability and cancer: the SOS-like hypothesis.
        Cancer Lett. 2006; 236: 1-12
        • Kamenisch Y.
        • Berneburg M.
        Progeroid syndromes and UV-induced oxidative DNA damage.
        J Investig Dermatol Symp Proc. 2009; 14: 8-14
        • Grier J.T.
        • Forbes L.R.
        • Monaco-Shawver L.
        • Oshinsky J.
        • Atkinson T.P.
        • Moody C.
        • et al.
        Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.
        J Clin Invest. 2012; 122: 3769-3780
        • Gineau L.
        • Cognet C.
        • Kara N.
        • Lach F.P.
        • Dunne J.
        • Veturi U.
        • et al.
        Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency.
        J Clin Invest. 2012; 122: 821-832
        • Chandesris M.O.
        • Melki I.
        • Natividad A.
        • Puel A.
        • Fieschi C.
        • Yun L.
        • et al.
        Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey.
        Medicine (Baltimore). 2012; 91: e1-19
        • Hagleitner M.M.
        • Lankester A.
        • Maraschio P.
        • Hulten M.
        • Fryns J.P.
        • Schuetz C.
        • et al.
        Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome).
        J Med Genet. 2008; 45: 93-99
        • de Greef J.C.
        • Wang J.
        • Balog J.
        • den Dunnen J.T.
        • Frants R.R.
        • Straasheijm K.R.
        • et al.
        Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2.
        Am J Hum Genet. 2011; 88: 796-804
        • Weemaes C.M.
        • van Tol M.J.
        • Wang J.
        • van Ostaijen-ten Dam M.M.
        • van Eggermond M.C.
        • Thijssen P.E.
        • et al.
        Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects.
        Eur J Hum Genet. 2013; 21: 1219-1225
        • Gennery A.R.
        • Slatter M.A.
        • Bredius R.G.
        • Hagleitner M.M.
        • Weemaes C.
        • Cant A.J.
        • et al.
        Hematopoietic stem cell transplantation corrects the immunologic abnormalities associated with immunodeficiency-centromeric instability-facial dysmorphism syndrome.
        Pediatrics. 2007; 120: e1341-e1344
        • Peron S.
        • Metin A.
        • Gardes P.
        • Alyanakian M.A.
        • Sheridan E.
        • Kratz C.P.
        • et al.
        Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination.
        J Exp Med. 2008; 205: 2465-2472
        • Stewart G.S.
        • Stankovic T.
        • Byrd P.J.
        • Wechsler T.
        • Miller E.S.
        • Huissoon A.
        • et al.
        RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling.
        Proc Natl Acad Sci U S A. 2007; 104: 16910-16915
        • Perlman S.
        • Becker-Catania S.
        • Gatti R.A.
        Ataxia-telangiectasia: diagnosis and treatment.
        Semin Pediatr Neurol. 2003; 10: 173-182
        • Bienemann K.
        • Burkhardt B.
        • Modlich S.
        • Meyer U.
        • Moricke A.
        • Bienemann K.
        • et al.
        Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.
        Br J Haematol. 2011; 155: 468-476
        • Masuda Y.
        • Kamiya K.
        Molecular nature of radiation injury and DNA repair disorders associated with radiosensitivity.
        Int J Hematol. 2012; 95: 239-245
        • Albert M.H.
        • Gennery A.R.
        • Greil J.
        • Cale C.M.
        • Kalwak K.
        • Kondratenko I.
        • et al.
        Successful SCT for Nijmegen breakage syndrome.
        Bone Marrow Transplant. 2010; 45: 622-626
        • Ussowicz M.
        • Musial J.
        • Duszenko E.
        • Haus O.
        • Kalwak K.
        Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL.
        Bone Marrow Transplant. 2013; 48: 740-741
        • Driscoll D.A.
        Molecular and genetic aspects of DiGeorge/velocardiofacial syndrome.
        Methods Mol Med. 2006; 126: 43-55
        • McDonald-McGinn D.M.
        • Sullivan K.E.
        Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
        Medicine (Baltimore). 2011; 90: 1-18
        • Sullivan K.E.
        Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial Syndrome.
        Immunol Allergy Clin North Am. 2008; 28: 353-366
        • Ciupe S.M.
        • Devlin B.H.
        • Markert M.L.
        • Kepler T.B.
        The dynamics of T-cell receptor repertoire diversity following thymus transplantation for DiGeorge anomaly.
        PLoS Comput Biol. 2009; 5: e1000396
        • Markert M.L.
        • Devlin B.H.
        • McCarthy E.A.
        Thymus transplantation.
        Clin Immunol. 2010; 135: 236-246
        • Selim M.A.
        • Markert M.L.
        • Burchette J.L.
        • Herman C.M.
        • Turner J.W.
        The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study.
        J Cutan Pathol. 2008; 35: 380-385
        • Patel K.
        • Akhter J.
        • Kobrynski L.
        • Gathman B.
        • Davis O.
        • Sullivan K.E.
        • et al.
        Immunoglobulin deficiencies: the B-lymphocyte side of DiGeorge Syndrome.
        J Pediatr. 2012; 161: 950-953
        • Tison B.E.
        • Nicholas S.K.
        • Abramson S.L.
        • Hanson I.C.
        • Paul M.E.
        • Seeborg F.O.
        • et al.
        Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome.
        J Allergy Clin Immunol. 2011; 128 (e1-3): 1115-1117
        • Bassett A.S.
        • McDonald-McGinn D.M.
        • Devriendt K.
        • Digilio M.C.
        • Goldenberg P.
        • Habel A.
        • et al.
        Practical guidelines for managing patients with 22q11.2 deletion syndrome.
        J Pediatr. 2011; 159: 332-339.e1
        • Johnson D.
        • Morrison N.
        • Grant L.
        • Turner T.
        • Fantes J.
        • Connor J.M.
        • et al.
        Confirmation of CHD7 as a cause of CHARGE association identified by mapping a balanced chromosome translocation in affected monozygotic twins.
        J Med Genet. 2006; 43: 280-284
        • Lalani S.R.
        • Safiullah A.M.
        • Molinari L.M.
        • Fernbach S.D.
        • Martin D.M.
        • Belmont J.W.
        SEMA3E mutation in a patient with CHARGE syndrome.
        J Med Genet. 2004; 41: e94
        • Janda A.
        • Sedlacek P.
        • Mejstrikova E.
        • Zdrahalova K.
        • Hrusak O.
        • Kalina T.
        • et al.
        Unrelated partially matched lymphocyte infusions in a patient with complete DiGeorge/CHARGE syndrome.
        Pediatr Transplant. 2007; 11: 441-447
        • Land M.H.
        • Garcia-Lloret M.I.
        • Borzy M.S.
        • Rao P.N.
        • Aziz N.
        • McGhee S.A.
        • et al.
        Long-term results of bone marrow transplantation in complete DiGeorge syndrome.
        J Allergy Clin Immunol. 2007; 120: 908-915
        • McGhee S.A.
        • Lloret M.G.
        • Stiehm E.R.
        Immunologic reconstitution in 22q deletion (DiGeorge) syndrome.
        Immunol Res. 2009; 45: 37-45
        • Zonios D.I.
        • Falloon J.
        • Bennett J.E.
        • Shaw P.A.
        • Chaitt D.
        • Baseler M.W.
        • et al.
        Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.
        Blood. 2008; 112: 287-294
        • Scott-Algara D.
        • Balabanian K.
        • Chakrabarti L.A.
        • Mouthon L.
        • Dromer F.
        • Didier C.
        • et al.
        Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4.
        Blood. 2010; 115: 3708-3717
        • Kuijpers T.W.
        • Ijspeert H.
        • van Leeuwen E.M.
        • Jansen M.H.
        • Hazenberg M.D.
        • Weijer K.C.
        • et al.
        Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations.
        Blood. 2011; 117: 5892-5896
        • Gorska M.M.
        • Alam R.
        Consequences of a mutation in the UNC119 gene for T cell function in idiopathic CD4 lymphopenia.
        Curr Allergy Asthma Rep. 2012; 12: 396-401
        • Cervera C.
        • Fernandez-Aviles F.
        • de la Calle-Martin O.
        • Bosch X.
        • Rovira M.
        • Plana M.
        • et al.
        Non-myeloablative hematopoietic stem cell transplantation in the treatment of severe idiopathic CD4+ lymphocytopenia.
        Eur J Haematol. 2011; 87: 87-91
        • Lev A.
        • Amariglio N.
        • Levy Y.
        • Spirer Z.
        • Anikster Y.
        • Rechavi G.
        • et al.
        Molecular assessment of thymic capacities in patients with Schimke immuno-osseous dysplasia.
        Clin Immunol. 2009; 133: 375-381
        • Kwan A.
        • Manning M.A.
        • Zollars L.K.
        • Hoyme H.E.
        Marked variability in the radiographic features of cartilage-hair hypoplasia: case report and review of the literature.
        Am J Med Genet A. 2012; 158A: 2911-2916
        • Taskinen M.
        • Toiviainen-Salo S.
        • Lohi J.
        • Vuolukka P.
        • Grasbeck M.
        • Makitie O.
        Hypoplastic anemia in cartilage-hair hypoplasia-balancing between iron overload and chelation.
        J Pediatr. 2013; 162: 844-849
        • Thiel C.T.
        • Rauch A.
        The molecular basis of the cartilage-hair hypoplasia-anauxetic dysplasia spectrum.
        Best Pract Res Clin Endocrinol Metab. 2011; 25: 131-142
        • Moore S.W.
        Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.
        Pediatr Surg Int. 2012; 28: 1045-1058
        • de la Fuente M.A.
        • Recher M.
        • Rider N.L.
        • Strauss K.A.
        • Morton D.H.
        • Adair M.
        • et al.
        Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.
        J Allergy Clin Immunol. 2011; 128: 139-146
        • Horn J.
        • Schlesier M.
        • Warnatz K.
        • Prasse A.
        • Superti-Furga A.
        • Peter H.H.
        • et al.
        Fatal adult-onset antibody deficiency syndrome in a patient with cartilage hair hypoplasia.
        Hum Immunol. 2010; 71: 916-919
        • Bordon V.
        • Gennery A.R.
        • Slatter M.A.
        • Vandecruys E.
        • Laureys G.
        • Veys P.
        • et al.
        Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation.
        Blood. 2010; 116: 27-35
        • Renner E.D.
        • Hartl D.
        • Rylaarsdam S.
        • Young M.L.
        • Monaco-Shawver L.
        • Kleiner G.
        • et al.
        Comel-Netherton syndrome defined as primary immunodeficiency.
        J Allergy Clin Immunol. 2009; 124: 536-543
        • Freeman A.F.
        • Holland S.M.
        Clinical manifestations of hyper IgE syndromes.
        Dis Markers. 2010; 29: 123-130
        • Schimke L.F.
        • Sawalle-Belohradsky J.
        • Roesler J.
        • Wollenberg A.
        • Rack A.
        • Borte M.
        • et al.
        Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis.
        J Allergy Clin Immunol. 2010; 126: 611-617.e1
        • Sowerwine K.J.
        • Holland S.M.
        • Freeman A.F.
        Hyper-IgE syndrome update.
        Ann N Y Acad Sci. 2012; 1250: 25-32
        • Roxo Jr., P.
        • Torres L.A.
        • Menezes U.P.
        • Melo J.M.
        Lung function in hyper IgE syndrome.
        Pediatr Pulmonol. 2013; 48: 81-84
        • Kumanovics A.
        • Perkins S.L.
        • Gilbert H.
        • Cessna M.H.
        • Augustine N.H.
        • Hill H.R.
        Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation.
        J Clin Immunol. 2010; 30: 886-893
        • Hsu A.P.
        • Sowerwine K.J.
        • Lawrence M.G.
        • Davis J.
        • Henderson C.J.
        • Zarember K.A.
        • et al.
        Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism.
        J Allergy Clin Immunol. 2013; 131: 1586-1593
        • Woellner C.
        • Gertz E.M.
        • Schaffer A.A.
        • Lagos M.
        • Perro M.
        • Glocker E.O.
        • et al.
        Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome.
        J Allergy Clin Immunol. 2010; 125: 424-432.e8
        • Al-Herz W.
        • Ragupathy R.
        • Massaad M.J.
        • Al-Attiyah R.
        • Nanda A.
        • Engelhardt K.R.
        • et al.
        Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait.
        Clin Immunol. 2012; 143: 266-272
        • Engelhardt K.R.
        • McGhee S.
        • Winkler S.
        • Sassi A.
        • Woellner C.
        • Lopez-Herrera G.
        • et al.
        Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome.
        J Allergy Clin Immunol. 2009; 124: 1289-1302.e4
        • Sanal O.
        • Jing H.
        • Ozgur T.
        • Ayvaz D.
        • Strauss-Albee D.M.
        • Ersoy-Evans S.
        • et al.
        Additional diverse findings expand the clinical presentation of DOCK8 deficiency.
        J Clin Immunol. 2012; 32: 698-708
        • Zhang Q.
        • Davis J.C.
        • Lamborn I.T.
        • Freeman A.F.
        • Jing H.
        • Favreau A.J.
        • et al.
        Combined immunodeficiency associated with DOCK8 mutations.
        N Engl J Med. 2009; 361: 2046-2055
        • Dasouki M.
        • Okonkwo K.C.
        • Ray A.
        • Folmsbeel C.K.
        • Gozales D.
        • Keles S.
        • et al.
        Deficient T cell receptor excision circles (TRECs) in autosomal recessive hyper IgE syndrome caused by DOCK8 mutation: implications for pathogenesis and potential detection by newborn screening.
        Clin Immunol. 2011; 141: 128-132
        • Conti H.R.
        • Baker O.
        • Freeman A.F.
        • Jang W.S.
        • Holland S.M.
        • Li R.A.
        • et al.
        New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome.
        Mucosal Immunol. 2011; 4: 448-455
        • Minegishi Y.
        • Saito M.
        Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome.
        Ann N Y Acad Sci. 2011; 1246: 34-40
        • Hirota K.
        • Ahlfors H.
        • Duarte J.H.
        • Stockinger B.
        Regulation and function of innate and adaptive interleukin-17-producing cells.
        EMBO Rep. 2012; 13: 113-120
        • Minegishi Y.
        • Karasuyama H.
        Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.
        Int Immunol. 2009; 21: 105-112
        • Kilic S.S.
        • Hacimustafaoglu M.
        • Boisson-Dupuis S.
        • Kreins A.Y.
        • Grant A.V.
        • Abel L.
        • et al.
        A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome.
        J Pediatr. 2012; 160: 1055-1057
        • Sassi A.
        • Lazaroski S.
        • Wu G.
        • Haslam S.M.
        • Fliegauf M.
        • Mellouli F.
        • et al.
        Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels.
        J Allergy Clin Immunol. 2014; 133 (e1-13): 1410-1419
        • Zhang Y.
        • Yu X.
        • Ichikawa M.
        • Lyons J.J.
        • Datta S.
        • Lamborn I.T.
        • et al.
        Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment.
        J Allergy Clin Immunol. 2014; 133 (e1-5): 1400-1409
        • Felgentreff K.
        • Siepe M.
        • Kotthoff S.
        • von Kodolitsch Y.
        • Schachtrup K.
        • Notarangelo L.D.
        • et al.
        Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome—contribution to new findings of immune dysregulation in connective tissue disorders.
        Clin Immunol. 2014; 150: 43-50
        • Has C.
        • Jakob T.
        • He Y.
        • Kiritsi D.
        • Hausser I.
        • Bruckner-Tuderman L.
        Loss of desmoglein 1 associated with palmoplantar keratoderma, dermatitis and multiple allergies.
        Br J Dermatol. 2015; 172: 257-261
        • Samuelov L.
        • Sarig O.
        • Harmon R.M.
        • Rapaport D.
        • Ishida-Yamamoto A.
        • Isakov O.
        • et al.
        Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting.
        Nat Genet. 2013; 45: 1244-1248
        • Esposito L.
        • Poletti L.
        • Maspero C.
        • Porro A.
        • Pietrogrande M.C.
        • Pavesi P.
        • et al.
        Hyper-IgE syndrome: dental implications.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114: 147-153
        • Belada D.
        • Smolej L.
        • Stepankova P.
        • Kralickova P.
        • Freiberger T.
        Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy.
        Leuk Res. 2010; 34: e232-e234
        • Bard S.
        • Paravisini A.
        • Aviles-Izquierdo J.A.
        • Fernandez-Cruz E.
        • Sanchez-Ramon S.
        Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab.
        Arch Dermatol. 2008; 144: 1662-1663
        • Chularojanamontri L.
        • Wimoolchart S.
        • Tuchinda P.
        • Kulthanan K.
        • Kiewjoy N.
        Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations.
        Asian Pac J Allergy Immunol. 2009; 27: 233-236
        • Gatz S.A.
        • Benninghoff U.
        • Schutz C.
        • Schulz A.
        • Honig M.
        • Pannicke U.
        • et al.
        Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation.
        Bone Marrow Transplant. 2011; 46: 552-556
        • Metin A.
        • Tavil B.
        • Azik F.
        • Azkur D.
        • Ok-Bozkaya I.
        • Kocabas C.
        • et al.
        Successful bone marrow transplantation for DOCK8 deficient hyper IgE syndrome.
        Pediatr Transplant. 2012; 16: 398-399
        • McDonald D.R.
        • Massaad M.J.
        • Johnston A.
        • Keles S.
        • Chatila T.
        • Geha R.S.
        • et al.
        Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency.
        J Allergy Clin Immunol. 2010; 126: 1304-1305.e3
        • Gennery A.R.
        • Flood T.J.
        • Abinun M.
        • Cant A.J.
        Bone marrow transplantation does not correct the hyper IgE syndrome.
        Bone Marrow Transplant. 2000; 25: 1303-1305
        • Goussetis E.
        • Peristeri I.
        • Kitra V.
        • Traeger-Synodinos J.
        • Theodosaki M.
        • Psarra K.
        • et al.
        Successful long-term immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome.
        J Allergy Clin Immunol. 2010; 126: 392-394